← All Macrogenics INC filings

Macrogenics INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
MGNX
Macrogenics INC
10-K: MacroGenics Reports 2024 Results, Highlights Pipeline Progress and Strategic Realignment
MacroGenics' 2024 10-K filing details financial results, pipeline advancements, and a strategic shift including the sale of MARGENZA.
NASDAQ
MGNX
Macrogenics INC
10-K: MacroGenics Reports 2023 Financial Results and Provides Pipeline Update
MacroGenics, a biopharmaceutical company, released its 2023 financial results and provided updates on its oncology pipeline, including progress on vobramitamab duocarmazine and lorigerlimab.